Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 11Active not recruiting 6Withdrawn 1Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Glioblastoma 6Breast Neoplasms 5Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Glioma 3Solid Tumors 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Melanoma 2Brain Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Papillomavirus Infections 1Pancreatic Ductal Adenocarcinoma 1PTEN Gene Mutation 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neuroma 1

Interventions

eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Leukemia, Myelomonocytic, Chronic × 30 days × Clear all
NCT06630221 2026-06-05

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Case Comprehensive Cancer Center

Phase 2 Suspended
25 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡